AI-Designed Drug Hints at Slowing Aging
TL;DR Summary
Insilico Medicine used generative artificial intelligence to design rentosertib, a small-molecule drug for a chronic lung condition. New clinical-trial data reported in Nature Biotechnology indicate the AI-designed drug reduced biological aging markers across six aging clocks, suggesting a potential to slow aging—but further research is needed to confirm safety, efficacy, and applicability beyond the lung disease context.
- Early Data Indicates an A.I.-Generated Drug Could Slow Aging The New York Times
- Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too WSJ
- AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says Bloomberg.com
- Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks Yahoo Finance
- Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial The Next Web
Reading Insights
Total Reads
1
Unique Readers
14
Time Saved
15 min
vs 16 min read
Condensed
98%
3,074 → 57 words
Want the full story? Read the original article
Read on The New York Times